An ongoing dialogue on HIV/AIDS, infectious diseases,
January 27th, 2010
No Vicriviroc — Yet
Apparently, Merck — taking over for Schering-Plough — will not seek approval for vicriviroc in treatment-experienced patients:
In two Phase III studies in this patient population, vicriviroc did not meet the primary efficacy endpoint. These studies enrolled a high percentage of patients who had three or more active drugs in their optimized background therapy regimen.
The report goes on to say that the results of these studies will be presented at CROI next month, and that other studies of vicriviroc in treatment-naive patients will continue.
Even though we don’t know the details yet, it’s understandable how this trial didn’t show any benefit for vicriviroc. With the “optimized background therapy” having 3 or more active drugs, how could it? We’re a long way from the TORO/T-20 days, when such “OBT” led to virologic suppression in < 10% of patients.
The control arms in these studies now just do too well. Progress!
Still, given the checkered history of this particular CCR5 antagonist — including a failed phase II study in treatment-naive patients and a possible signal of increased malignancies in another trial — the FDA approval for any indication might be a long hill to climb.
Categories: HIV
Tags: antiretroviral, CCR5 antagonists, HIV, vicriviroc
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.

Paul E. Sax, MD
Contributing Editor
NEJM Journal Watch
Infectious Diseases
Biography | Disclosures | Summaries
Learn more about HIV and ID Observations.
Search this Blog
Follow HIV and ID Observations Posts via Email
Archives
-
-
From the Blog — Most Recent Articles
- My Dog Louie, the Best Dog Ever, Is Seriously Ill September 26, 2025
- Two Drugs, Not Three: The DOLCE Study in Advanced HIV Disease September 19, 2025
- When Required Learning Modules Surprise You (In a Good Way) September 10, 2025
- End-of-Summer Musings — Hepatitis B, Dalbavancin, Alpha-Gal, and More September 4, 2025
- Watching the Chaos at the CDC — with Sadness and Alarm August 29, 2025
NEJM Journal Watch — Recent Infectious Disease Articles
- Can Recombinant Technology Improve Rabies Prevention?
- Is the High-Dose Flu Vaccine Better Than the Standard Dose for Preventing Severe Outcomes?
- Observations from ID and Beyond: Two Drugs, Not Three — The DOLCE Study in Advanced HIV Disease
- Marburg Outbreak! Can Rapid Response Minimize Mortality and Halt Spread?
- The Ryan White HIV/AIDS Program: Critical to Efforts to End the HIV Epidemic
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease medical education MRSA PEP PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster